Soldan, Samantha S.
Anderson, Emma M.
Frase, Drew M.
Zhang, Yue
Caruso, Lisa B.
Wang, Yin
Deakyne, Julianna S.
Gewurz, Benjamin E.
Tempera, Italo
Lieberman, Paul M.
Messick, Troy E. http://orcid.org/0000-0001-7914-1524
Funding for this research was provided by:
National Cancer Institute (RO1-CA093606, P30-CA010815)
National Institute of Dental and Craniofacial Research (RO1-DE017336)
National Institutes of Health (1-S10-OD021669-01A1)
National Institute of Allergy and Infectious Diseases (R01-AI37337)
National Cancer Institute (R01-CA228700)
Article History
Received: 23 December 2020
Accepted: 20 April 2021
First Online: 30 April 2021
Declarations
:
: This work was partially funded through a sponsored research agreement with Cullinan Apollo. The Wistar Institute on behalf of the authors T.E.M. and P.M.L. have filed patents covering composition of matter and their use on the small molecules disclosed here for the treatment of human cancer and other diseases (patent number WO2015073864, “EBNA1 Inhibitors and Their Method of Use”; WO2016183534, “EBNA1 Inhibitors and Methods using Same”). P.M.L. has an ownership interest in Vironika, LLC.
Free to read: This content has been made available to all.